27 February 2024 - Mabwell announces that its self developed novel antibody drug conjugate targeting Nectin-4 (9MW2821) has been granted fast track designation by the US FDA for the treatment of advanced, recurrent, or metastatic oesophageal squamous cell carcinoma.

9MW2821 is a site specific conjugated novel Nectin-4-targeting antibody drug conjugate developed by Mabwell's antibody drug conjugate platform and automated high-throughput hybridoma antibody molecular discovery platform, and is the first clinical stage Nectin-4-targeting antibody drug conjugate developed by Chinese company.